Medicine composition containing berberine and sophocarpidine, and purpose of medicine composition for treating or preventing non-alcoholic fatty liver disease

A fatty liver disease, non-alcoholic technology, applied in the field of biopharmaceuticals, can solve the problems of no clear treatment method, no definite treatment effect of liver fibrosis, etc.

Pending Publication Date: 2021-09-10
INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] 2. Morbidity
2. Drug treatment for metabolic syndrome: such as obesity, hypertension and type 2 diabetes, etc., but currently these drugs have no certain therapeutic effect on NAFLD, especially liver fibrosis
3. Bariatric surgery: Sleeve gastrectomy is the most commonly used in Asian countries, but there is not enough evidence to recommend bariatric surgery for NAFLD
As noted above, there is currently no definitive treatment other than reasonable exercise and lifestyle changes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition containing berberine and sophocarpidine, and purpose of medicine composition for treating or preventing non-alcoholic fatty liver disease
  • Medicine composition containing berberine and sophocarpidine, and purpose of medicine composition for treating or preventing non-alcoholic fatty liver disease
  • Medicine composition containing berberine and sophocarpidine, and purpose of medicine composition for treating or preventing non-alcoholic fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0090] Experimental method and material

[0091] 1.1 Experimental animals: LVG Syrian golden earth rat, male, 4 weeks old, weight 70-90g, the feeding environment adapted for 2 weeks. Animals were purchased from Beijing Virong Lihua Experimental Animal Technology Co., Ltd.

[0092] 1.2 Experiment Feed: Basic Feed (Normal Chow Diet, White Group); High Fat Diet, Model Group: 1.0% Cholesterol, 0.2% Cholina, 10.0% Laust, 5.0% Egg Yellow Powder and 83.8% Basal Feed ). Feed is purchased from Beijing Keo Cooperation Feed Co., Ltd.

[0093] 1.3 Administration: 1) Preventive Group: Simultaneous administration with high-fat feed, mix the drug in high fat feed, 12 weeks for continuous administration. 2) Treatment group: The high-fat feed was administered after 8 weeks of administration, and it was administered for 10 weeks. Berberine and bitter ginsee were purchased from Nanjing Zelan Biotechnology Co., Ltd.

[0094] 1.4 Experimental grouping and dose of dose:

[0095]

[0096] 1.5 detectio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicine composition containing berberine and sophocarpidine, and a purpose of the medicine composition for treating or preventing the non-alcoholic fatty liver disease (NAFLD) (including non-alcoholic fatty hepatitis (NASH)). Specifically, the medicine composition of the invention comprises a berberine compound and a matrine compound as active ingredients. Two active components have a synergistic effect, can significantly reduce key indexes of the NAFLD (including NASH), namely triglyceride content in liver tissues, oxidative stress and chronic inflammatory reaction, and also can lower the blood fat level and the liver index.

Description

Technical field [0001] The present invention relates to pharmaceutical compositions comprising berberine and bitterine and its use or prevent non-alcoholic fatty liver disease, belong to the field of biopharmaceutical. Background technique [0002] Non-alcoholic fatty liver disease [0003] Nonalcoholic Fatty Liver disease (NAFLD) is the performance of metabolic syndrome in the liver, is a metabolic shoulder liver injury associated with insulin resistance and genetic susceptibility, and is complicated with insulin resistance and metabolism. High-risk related to 2 type diabetes, arteriosclerosis cardiovascular diseases and colorectal tumors. In the clinic, the preliminary diagnosis of NAFLD refers to ≥5% liver fat accumulation without other recognized factors such as alcohol, viruses, drugs, autoimmunity. NAFLD is characterized by the abnormal accumulation of triglycerides in the liver. In the case of no inflammation and hepatocyte damage, it is defined as fat degeneration or non-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4375A61P1/16A61P3/06
CPCA61K31/4375A61P1/16A61P3/06A61K2300/00
Inventor 蒋建东樊伟明王璐璐蒋卫郭慧慧傅小峰李晓琳
Owner INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap